Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of VSA001 in Chinese Healthy Volunteers
NCT05757596Phase 1Completed
- Sponsor
- Visirna Therapeutics
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in familial chylomicronemia syndrome (FCS) and hypertriglyceridemia comparing VSA001 injection with Placebo (2 arms). Primary endpoint: Safety and tolerability at 85 days. Started May 2023; status: completed.
02
Drugs
plozasiran
03
Conditions
familial chylomicronemia syndrome (FCS)hypertriglyceridemia
Beyond the preview
Go deeper on NCT05757596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757596.